Idiopathic pulmonary fibrosis (IPF) is a highly heterogeneous, unpredictable and ultimately
lethal chronic lung disease. Over the last decade, two anti-fibrotic agents have been shown …

Fibrosis, or tissue scarring, develops as a pathological deviation from the physiological
wound healing response and can occur in various organs such as the heart, lung, liver …

Pulmonary fibrosis (PF) encompasses a spectrum of chronic lung diseases that
progressively impact the interstitium, resulting in compromised gas exchange …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …

Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic
interstitial pneumonia, characterized by chronic, progressive, and low survival rates, while …

Fibrosis is a consequence of the pathological remodeling of extracellular matrix (ECM)
structures in the connective tissue of an organ. It is often caused by chronic inflammation …

Idiopathic pulmonary fibrosis is defined as a chronic progressive fibrosing interstitial
pneumonia of unknown etiology. There are intrinsic and extrinsic risk factors that could favor …

Idiopathic pulmonary fibrosis (IPF) represents a chronic progressive fibrotic interstitial lung
disease of unknown cause with an ominous prognosis. It remains an unprecedent clinical …

Disease progression (DP) is an important parameter for the prognosis of idiopathic
pulmonary fibrosis (IPF). This study aimed to evaluate the baseline serum biomarkers for …